• Keith A Wesnes, Dag Aarsland, Clive Ballard, and Elisabet Londos.
• Wesnes Cognition Ltd, Streatley on Thames, UK; Department of Psychology, Northumbria University, Newcastle, UK; Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia.
• Int J Geriatr Psychiatry. 2015 Jan 1;30(1):46-54.

ObjectiveIn both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), attentional dysfunction is a core clinical feature together with disrupted episodic memory. This study evaluated the cognitive effects of memantine in DLB and PDD using automated tests of attention and episodic memory.MethodsA randomised double-blind, placebo-controlled, 24-week three centre trial of memantine (20 mg/day) was conducted in which tests of attention (simple and choice reaction time) and word recognition (immediate and delayed) from the CDR System were administered prior to dosing and again at 12 and 24 weeks. Although other results from this study have been published, the data from the CDR System tests were not included and are presented here for the first time.ResultsData were available for 51 patients (21 DLB and 30 PDD). In both populations, memantine produced statistically significant medium to large effect sized improvements to choice reaction time, immediate and delayed word recognition.ConclusionsThese are the first substantial improvements on cognitive tests of attention and episodic recognition memory identified with memantine in either DLB or PDD.Copyright © 2014 John Wiley & Sons, Ltd.

30 keywords...

hide…